you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects
Reduced Food and Fluid Intake Because Semaglutide reduces appetite, many people eat less while taking it
What it can support is the physical comfort side of weaning, reduced pumping, dropped feeds, and feeding transitions
Semaglutide helped me find balance. Addressing Common Concerns Many potential users may have questions about side effects or how long it takes to see results with semaglutide
As mentioned previously, a clinical trial (SURPASS-CVOT) is currently underway that aims to shed light on tirzepatides ability to mitigate cardiovascular risk
